BAGSVAERD, DENMARK--(Marketwire - February 15, 2010) -
Novo Nordisk A/S - Share repurchase programme
On 2 February 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010.
Since the announcement as of 8 February 2010, the following transactions have been made under the programme:
Number of shares Average purchase Transaction value, price DKK Accumulated, last 435,000 162,272,753 announcement 08 February 2010 90,000 373.8999 33,650,991 09 February 2010 90,000 374.0000 33,660,000 10 February 2010 90,000 374.0290 33,662,610 11 February 2010 90,000 378.7490 34,087,410 12 February 2010 90,000 385.0110 34,650,990 Accumulated under the 885,000 331,984,754 programme
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 359,222 B shares in the period from 8 February 2010 to 12 February 2010. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 31,281,948 treasury shares, corresponding to 5.0% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit novonordisk.com.
Further information: Media: Investors: Elin K Hansen Klaus Bulow Davidsen Tel: (+45) 4442 3450 Tel: (+45) 4442 3176 ekh@novonordisk.com klda@novonordisk.com Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 krop@novonordisk.com In North America: In North America: Sean Clements Hans Rommer Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937 secl@novonordisk.com hrmm@novonordisk.com
Company Announcement no 9 / 2010
[HUG#1384418]
Company Announcement no 9 2010: http://hugin.info/2013/R/1384418/343190.pdf
